Upcoming IPOs
Expected Listing Date: - -
Biotechnology & Medical Research
Public Filing
View Prospectus
Price Range: Pending
Shares to be Issued: Pending
Offering End Date
Offering Price: Pending
Post IPO Outstanding: 58.85M
BRIEF-Century Therapeutics Reports Full Year 2022 Financial Results
Reuters · 4d ago
BRIEF-Century Therapeutics Maintains About $3 Mln Of Cash, Cash Equivalents With SVB
Reuters · 03/13 12:34
CRISPR Layoffs 2023: Job Cuts Hit Gene-Editing Stocks FATE, TCRR, IPSC
Investor Place · 01/06 20:48
BRIEF-Century Therapeutics Announces Internal Portfolio Prioritization To Extend Cash Runway Into 2026
Reuters · 01/05 22:04
Further weakness as Century Therapeutics (NASDAQ:IPSC) drops 12% this week, taking one-year losses to 39%
Investors can approximate the average market return by buying an index fund. But if you buy individual stocks, you can...
Simply Wall St. · 12/08/2022 15:02
BRIEF-Century Therapeutics Provides Pipeline Updates
Reuters · 11/11/2022 12:15
Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates
- Preclinical data support next generation platform for iPSC-derived NK cells with multiple gene edits to improve persistence and anti-tumor efficacy - - iPSC-derived CAR gamma delta T cells shown to effectively control solid tumors as monotherapy and in c...
GlobeNewswire · 11/11/2022 12:00
Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates
Century Therapeutics, Inc. (IPSC) delivered earnings and revenue surprises of 10.17% and 42.11%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/10/2022 13:45
About IPSC
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic, pluripotent stem cells (iPSC)-derived natural killer (NK) and T cell therapies to create products for the treatment of both solid tumor and hematological malignancies. Its Allo-Evasion technology is intended to prevent rejection of cell products by the host immune system, and manufacturing capabilities intended to minimize product development and supply risk. The Company's pipeline includes CNTY-101, CNTY-103, CNTY-102 and CNTY-104. The Company’s lead product candidate, CNTY-101, is focused on targeting B-cell lymphoma. CNTY-103 is designed to treat glioblastoma. CNTY-102 is designed to improve B-cell malignancy treatment. CNTY-104, is being developed to treat acute myeloid leukemia (AML). CAR design is a component of cell therapy product candidates. In addition to its programs, the Company is also actively engaged in a number of earlier stage discovery programs.

Webull offers kinds of IPSCO TUBULARS stock information, including NYSE:IPSC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IPSC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IPSC stock methods without spending real money on the virtual paper trading platform.